RA CAPITAL MANAGEMENT, L.P. - 06 Jul 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director, 10%+ Owner
Signature: /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol: ABOS
Transactions as of: 06 Jul 2021
Net transactions value: +$30,000,000
Form type: 4
Filing time: 08 Jul 2021, 16:32:55 UTC
Previous filing: 06 Jul 2021
Next filing: 22 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+6,122,557			6,122,557	06 Jul 2021	See footnotes	F1, F2, F5
transaction	ABOS	Common Stock	Purchase	$28,149,312	+1,759,332	+29%	$16.00	7,881,889	06 Jul 2021	See footnotes	F2, F5
transaction	ABOS	Common Stock	Conversion of derivative security		+1,184,366			1,184,336	06 Jul 2021	See footnotes	F1, F3, F5
transaction	ABOS	Common Stock	Purchase	$1,850,688	+115,668	+9.8%	$16.00	1,300,034	06 Jul 2021	See footnotes	F3, F5
transaction	ABOS	Common Stock	Conversion of derivative security		+588,850			588,850	06 Jul 2021	See footnotes	F1, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series B Preferred Stock	Conversion of derivative security	$0	-6,122,557	-100%	$0.000000^*	0	06 Jul 2021	Common Stock	6,122,557		See footnotes	F1, F2, F5
transaction	ABOS	Series B Preferred Stock	Conversion of derivative security	$0	-1,184,366	-100%	$0.000000^*	0	06 Jul 2021	Common Stock	1,184,366		See footnotes	F1, F3, F5
transaction	ABOS	Series B Preferred Stock	Conversion of derivative security	$0	-588,850	-100%	$0.000000^*	0	06 Jul 2021	Common Stock	588,850		See footnotes	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3	These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F4	These securities are held directly by a separately managed account (the "Account").
F5	RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.